1. Une ostéonécrose iatrogène
- Author
-
Hélène Geniaux, Jacques Buxeraud, Sylvain Dumond, Faculty of science II [Fanar], Lebanese University [Beirut] (LU), Faculté de Pharmacie [Limoges], and Université de Limoges (UNILIM)
- Subjects
0301 basic medicine ,Pharmacology ,Gynecology ,medicine.medical_specialty ,Bevacizumab ,business.industry ,[SDV]Life Sciences [q-bio] ,Cancer ,Disease ,medicine.disease ,3. Good health ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Breast cancer ,030220 oncology & carcinogenesis ,Pharmacovigilance ,medicine ,Pharmacology (medical) ,Blood supply ,Femur ,Adverse effect ,business ,medicine.drug - Abstract
EnglishOsteonecrosis is the abnormal and premature deterioration of bone tissue due to an interruption of the blood supply. The disease mainly affects long bones such as the femur but can also affect short bones. There are a number of causes of this condition which can be induced by medicines such as bisphosphonates. A pharmacovigilance case report flagged an adverse event with bevacizumbab used to treat breast cancer. francaisL’osteonecrose est une degradation anormale et prematuree d’un tissu osseux due a un defaut de vascularisation. La maladie touche principalement des os longs comme le femur mais aussi des os courts. Il existe de nombreuses causes a cette pathologie qui peut etre induite par des medicaments comme les bisphosphonates. Un cas de pharmacovigilance avec le bevacizumab utilise dans un contexte de cancer du sein a ete signale
- Published
- 2019
- Full Text
- View/download PDF